Golden Shrimp Seafood's frozen yellowfin tuna had an inadequate seafood safety plan for controlling histamine.
What happened
FDA inspected the company's seafood processing facility in Tuy Hoa, Vietnam, on December 11 and 12, 2023, after a consumer complaint of histamine poisoning from saku, cubed, and ground yellowfin tuna. FDA found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) rule, which requires processors to have and follow a seafood safety plan. The company's plan lacked adequate limits for histamine control, and its response did not include an updated HACCP plan or documentation showing its new sampling procedures were incorporated.
What FDA found
The company's seafood safety plan did not set an adequate critical limit (the required control value) for histamine at a critical control point, and its sampling limit did not show that its sampling procedures were representative of all fish in the sample.
21 CFR 123.6(c)(3)The seafood safety plan did not set a critical limit for controlling histamine when fish are unloaded from harvest vessels.
21 CFR 123.6(c)(3)
What FDA wants
FDA tells the company to respond in writing within 15 working days of receipt with the specific corrections, including a revised HACCP plan and completed monitoring records for five consecutive production date codes. If corrections cannot be completed in that time, the company must explain the delay and state when it will finish.
Who should pay attention
- seafood importers and distributors sourcing frozen tuna from Vietnam
- brands using contract processors for histamine-forming fish
- retailers and foodservice buyers of frozen yellowfin tuna
This is a summary. Read the original letter on fda.gov.